Industry Bodies Warn Against Switching Among Biosimilars
EFPIA, the EBE and the IFPMA have issued a joint position paper in which they address a number of issues relating to biosimilars, including a caution against switching patients from one biosimilar of a reference drug to another.
You may also be interested in...
Two patient advocacy groups have said that a number of issues surrounding biosimilar switching, patient consent and traceability remain to be addressed in Europe, despite growing support for biosimilar use from physician bodies and clinical studies. But the European biosimilars industry has dismissed these concerns, saying that biosimilar medicines will significantly improve access to biologics patients while contributing to the sustainability of pharmaceutical budgets.
The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.
As discussions continue over the European Commission’s plans to overhaul the EU pharmaceutical legislation, the R&D-based pharma industry body EFPIA says that any new pharma policy framework will need to be stable, fast, effective and globally competitive.